{Reference Type}: Journal Article
{Title}: Multi-target drugs for Alzheimer's disease.
{Author}: Turgutalp B;Kizil C;
{Journal}: Trends Pharmacol Sci
{Volume}: 45
{Issue}: 7
{Year}: 2024 Jul 8
{Factor}: 17.638
{DOI}: 10.1016/j.tips.2024.05.005
{Abstract}: Alzheimer's disease (AD), a leading cause of dementia, increasingly challenges our healthcare systems and society. Traditional therapies aimed at single targets have fallen short owing to the complex, multifactorial nature of AD that necessitates simultaneous targeting of various disease mechanisms for clinical success. Therefore, targeting multiple pathologies at the same time could provide a synergistic therapeutic effect. The identification of new disease targets beyond the classical hallmarks of AD offers a fertile ground for the design of new multi-target drugs (MTDs), and building on existing compounds have the potential to yield in successful disease modifying therapies. This review discusses the evolving landscape of MTDs, focusing on their potential as AD therapeutics. Analysis of past and current trials of compounds with multi-target activity underscores the capacity of MTDs to offer synergistic therapeutic effects, and the flourishing genetic understanding of AD will inform and inspire the development of MTD-based AD therapies.